ServBlock Secures EU Funding For Pharma Manufacturing Data Space

European News

ServBlock secures EU funding for pharma manufacturing data space

ServBlock, an Irish start-up, and Irish Manufacturing Research (IMR), have been given EU funding to build a data exchange system for outsourced pharmaceutical manufacturing.

ServBlock is a company that uses blockchain-based auditing and compliance to help pharma manufacturers guarantee quality across their supply chain. It aims to automate pharmaceutical compliance to make it more secure, timely and cost-efficient with the use of blockchain technology.

It is also leading an Irish consortium, which is being used as a test case for trusted data transfer in pharma supply chains, and has members such as Cork ’s Nexa Enterprise Asset Management, Dublin’s Ingeniero Solutions, Limerick ’s Union Process Solutions and Waterford’s Plant Quest.

A data space brings together multiple channels of data to make it more easily accessible for various reasons and this consortium data space will work to gain insight into the efficiency and competitiveness of the pharma manufacturing process. This EU funding will help bring in more experts to help further develop the data space, with experts coming from various fields including data science, manufacturing and engineering.

ServBlock was given the funding alongside IMR, a research and technology organisation, which researches emerging technologies for advanced manufacturing.

“IMR are excited to participate in this consortium and facilitate improvements in patient outcomes through improvements to pharmaceutical manufacturing and supply chain,” commented Adrian Hovenden, IMR industrial solutions architect. He also stated that collaboration to create impactful results is key to “ensuring the continued growth and development” in the Irish manufacturing sector.

CHMP grants positive opinion to ViiV Healthcare’s cabotegravir for HIV prevention

GSK has announced that ViiV healthcare has received a positive opinion from the EMA's CHMP, recommending marketing authorisation for cabotegravir long-acting (LA) injectable and tablets for HIV prevention.

European Parliament shares goal to tackle antimicrobial resistance

The European Parliament has shared its recommendations for a ‘coordinated EU response to health threats posed by antimicrobial resistance,’ according to its press release.

European Commission delays release of major changes to pharma legislation

The European Commission (EC) has again delayed the release of its new proposal for changes to Europe’s pharma legislation. The decision was previously expected on 29 March 2023, but has been announced to be “slightly later”.

AstraZeneca’s NMOSD treatment recommended marketing

Pharma giant AstraZeneca has been given a recommendation by the EU's Committee for Medicinal Products (CHMP) for marketing authorisation for ultomiris (ravulizumab), a treatment for adult patients with neuromyelitis optica spectrum disorder (NMSOD) who are anti-aquaporin-4 (AQP4) antibody positive (ab+).

AbbVie gains positive CHMP opinion for upadacitinib for the treatment of Crohn’s disease

AbbVie has announced that it has received positive feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) recommending the approval of upadacitinib (rinvoq) for the treatment of adult patients with moderate to severe crohn’s disease who have had an inadequate response, lost response or were intolerant to conventional therapies or biologic agents.

CHMP grants positive opinion to ViiV Healthcare’s cabotegravir for HIV prevention

European Parliament shares goal to tackle antimicrobial resistance

European Commission delays release of major changes to pharma legislation

AstraZeneca’s NMOSD treatment recommended marketing

AbbVie gains positive CHMP opinion for upadacitinib for the treatment of Crohn’s disease

Pharmafocus

Categories

Social Footprints